NAVB · Navidea Biopharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | - | $7.5K | $57.5K | $0 | - | $96.4K | $261.0K |
| Cost of Revenue | - | - | - | - | $1.4K | $473 | $0 | - | $0 | $0 |
| Gross Profit | $0 | $0 | - | - | ($126.9K) | $57.1K | $0 | - | $96.4K | $261.0K |
| R&D | $829.6K | $1.11M | $1.27M | - | $1.19M | $1.72M | $1.17M | - | $1.05M | $1.50M |
| SG&A | $1.30M | $1.32M | $1.15M | - | $3.64M | $1.26M | $1.81M | - | $1.47M | $1.43M |
| Total Operating Expenses | $2.13M | $2.43M | $2.42M | - | $4.82M | $2.98M | $2.98M | - | $2.52M | $2.93M |
| D&A | $27.0K | $27.1K | $27.6K | - | $24.7K | $21.8K | $22.9K | - | $18.1K | $19.9K |
| Operating Income | ($2.13M) | ($2.43M) | ($2.42M) | - | ($4.95M) | ($2.92M) | ($2.98M) | - | ($2.42M) | ($2.67M) |
| Interest Expense | $98.4K | $160.7K | $151.5K | - | $100.7K | $83.6K | - | - | $0 | $1.0K |
| Income Tax | - | - | - | - | $0 | - | - | - | $0 | - |
| Net Income | ($2.26M) | $5.82M | ($1.48M) | - | ($2.44M) | ($3.00M) | ($2.99M) | - | ($2.44M) | ($2.67M) |
| EPS - Basic | ($0.02) | $0.12 | ($0.05) | - | ($0.08) | ($0.09) | ($0.11) | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.86M | $6.14M | $33.8K | $2.00M | $4.60M | $328.0K | $1.22M | $4.23M | $7.18M | $7.11M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $460.7K | $460.7K | $460.6K | $427.3K | $193.8K | $315.7K | $323.0K | $151.2K | $178.9K | $178.8K |
| Accounts Payable | - | $2.01M | $3.17M | $2.12M | $1.74M | $2.43M | $1.56M | $1.42M | $1.21M | $1.08M |
| Current Assets | $4.50M | $7.00M | $1.20M | $3.20M | $5.10M | $1.17M | $2.32M | $5.38M | $7.66M | $10.04M |
| Total Assets | $5.70M | $8.22M | $2.37M | $4.37M | $6.26M | $2.50M | $3.60M | $6.64M | $8.96M | $11.28M |
| Current Liabilities | $7.98M | $8.31M | $9.25M | $9.94M | $8.43M | $5.32M | $4.90M | $5.30M | $4.10M | $4.02M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.68M | $9.01M | $11.92M | $12.51M | $10.93M | $6.74M | $5.71M | $6.02M | $4.83M | $4.85M |
| Stockholders' Equity | ($3.27M) | ($1.08M) | ($9.84M) | ($8.44M) | ($4.96M) | ($4.53M) | ($2.40M) | ($106.6K) | $3.40M | $5.70M |
| Retained Earnings | ($385.91M) | ($383.65M) | ($389.48M) | ($388.00M) | ($384.52M) | ($376.77M) | ($373.77M) | ($370.79M) | ($367.14M) | ($364.70M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.72M) | - | - | - | ($2.56M) | - | - | - |
| Investing Cash Flow | - | - | ($39.4K) | - | - | - | ($118.2K) | - | - | - |
| Financing Cash Flow | - | - | ($200.5K) | - | - | - | ($339.5K) | - | - | - |
| CapEx | - | - | $15.1K | - | $14.4K | $48.7K | $0 | - | $18.0K | $2.7K |
| Free Cash Flow | - | - | ($1.74M) | - | - | - | ($2.56M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | -1688.7% | 99.2% | - | - | 100.0% | 100.0% |
| Operating margin | - | - | - | - | -65870.0% | -5080.5% | - | - | -2512.7% | -1022.7% |
| EBITDA margin | - | - | - | - | -65541.4% | -5042.6% | - | - | -2493.9% | -1015.1% |
| Net margin | - | - | - | - | -32435.3% | -5214.1% | - | - | -2529.3% | -1024.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.18 | - | - | - | 0.86 | - | - | - |
| R&D / Revenue | - | - | - | - | 15785.2% | 2996.9% | - | - | 1088.2% | 573.9% |
| SG&A / Revenue | - | - | - | - | 48396.1% | 2182.8% | - | - | 1524.5% | 548.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -39.6% | 70.9% | -62.4% | - | -39.0% | -119.8% | -82.9% | - | -27.2% | -23.7% |
| Return on equity | 68.9% | -539.8% | 15.0% | - | 49.2% | 66.2% | 124.4% | - | -71.6% | -46.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.56 | 0.84 | 0.13 | 0.32 | 0.60 | 0.22 | 0.47 | 1.02 | 1.87 | 2.50 |
| Quick ratio | 0.51 | 0.79 | 0.08 | 0.28 | 0.58 | 0.16 | 0.41 | 0.99 | 1.83 | 2.45 |
| Cash ratio | 0.48 | 0.74 | 0.00 | 0.20 | 0.55 | 0.06 | 0.25 | 0.80 | 1.75 | 1.77 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -21.7x | -15.1x | -16.0x | - | -49.2x | -35.0x | - | - | - | -2669.6x |
| Equity multiplier | -1.74 | -7.62 | -0.24 | -0.52 | -1.26 | -0.55 | -1.50 | -62.36 | 2.63 | 1.98 |
| Liabilities / Assets | 1.52 | 1.10 | 5.03 | 2.86 | 1.75 | 2.69 | 1.59 | 0.91 | 0.54 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | - | - | 0.00 | 0.02 | 0.00 | - | 0.01 | 0.02 |
| Inventory turnover | - | - | - | - | 0.01 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | 49399d | 243593d | - | - | - | - |
| Days payable outstanding | - | - | - | - | 443128d | 1872575d | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | -100.0% | - | - | -92.2% | -78.0% | -100.0% | - | -64.1% | -3.7% |
| Revenue CAGR (3y) | - | - | - | - | -68.3% | -39.5% | - | - | -25.3% | -21.6% |
| Revenue CAGR (5y) | - | - | - | - | -49.3% | -37.7% | - | - | -59.2% | -45.4% |
| Gross profit growth (YoY) | - | - | - | - | - | -78.1% | - | - | -64.1% | -3.6% |
| Operating income growth (YoY) | 56.9% | 16.9% | 18.7% | - | -104.4% | -9.5% | 10.5% | - | 16.5% | -14.1% |
| Net income growth (YoY) | 7.5% | - | 50.6% | - | 0.0% | -12.2% | -0.7% | - | 26.2% | -11.3% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 32.0% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 34.0% | 76.2% | -309.7% | -7816.8% | - | - | - | - | 1903.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$531.5K totalDiagnostics Segment$531.5K · 100.0%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing NAVIDEA BIOPHARMACEUTICALS against the 5 most active filers in the same SIC group.